Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002533393 | SCV000770743 | likely benign | Dyskeratosis congenita, autosomal dominant 2; Idiopathic Pulmonary Fibrosis | 2023-09-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004559292 | SCV002608805 | uncertain significance | Dyskeratosis congenita | 2022-08-30 | criteria provided, single submitter | clinical testing | The p.T1030R variant (also known as c.3089C>G), located in coding exon 14 of the TERT gene, results from a C to G substitution at nucleotide position 3089. The threonine at codon 1030 is replaced by arginine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004533396 | SCV004117906 | uncertain significance | TERT-related disorder | 2022-11-08 | criteria provided, single submitter | clinical testing | The TERT c.3089C>G variant is predicted to result in the amino acid substitution p.Thr1030Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0083% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-1255470-G-C). In ClinVar, this variant is interpreted as uncertain (https://preview.ncbi.nlm.nih.gov/clinvar/variation/539224/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |